Correction of press release published on 3 September 2024 regarding first commercial order on a TSE SYSTEM
Scandinavian ChemoTech published a press release on 3 September 2024 regarding a first commercial order on a TSE SYSTEM. In the press release, the counterparty’s name was mentioned which was not allowed under the agreement with the counterparty. Below is a correct press release without the counterparty’s name and a clarification that the order of the TSE system includes consumables.
Animal Care Receives its First Commercial Order for a TSE System from a Large Animal Clinic in Sweden
Scandinavian ChemoTech’s subsidiary Vetiqure AB, proudly announces an order, for a complete TSE system including consumables, worth approximately EUR 40,000 from a prominent a leading clinic in oncological animal care in Sweden, which is a part of one of the largest veterinary medicine organisations.
This significant order is a result of an extensive evaluation period where the hospital evaluated vetIQure™ and the TSE treatment.
"We are happy to be able to continue to build on our relationship and hope that this collaboration will expand to other hospitals and clinics in Europe and the USA," says Mohan Frick, CEO of Scandinavian ChemoTech and Vetiqure. "This order is a testament to hard work and validates the innovative solutions we have developed to meet the needs of the veterinary and animal care industry. We look forward to a continued successful partnership that will drive growth and create new opportunities for both companies."
As Vetiqure AB continues its journey and begins a new chapter, our focus will continue to be on providing world-class innovation. This marks a continued investment in improving methods and contributes to the establishment of new standards in veterinary medicine's cancer and tumour care.
For further information please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
E-mail: ir@chemotech.se
Certified Adviser: Redeye AB
Denna information är sådan som ChemoTech är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning (EU nr 596/2014). Informationen lämnades, genom angiven kontaktpersons försorg, för offentliggörande 2024-09-03 09:13 CET.
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.